Clinical Trials Logo

Herpes Genitalis clinical trials

View clinical trials related to Herpes Genitalis.

Filter by:

NCT ID: NCT01132729 Completed - Herpes Zoster Clinical Trials

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions

Start date: September 2006
Phase: N/A
Study type: Interventional

The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fasting conditions.

NCT ID: NCT01132716 Completed - Herpes Zoster Clinical Trials

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions

Start date: September 2006
Phase: N/A
Study type: Interventional

The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fed conditions.

NCT ID: NCT01112956 Completed - Genital Herpes Clinical Trials

Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2

Start date: July 2009
Phase: N/A
Study type: Observational

The purposes of this study are: - To determine the accuracy of commercially available serologic assays in diagnosing patients with herpes simplex virus type 2 (HSV-2); - To assess the sensitivity and specificity of the commerical assays using HSV-2 western blot as the "gold standard" in a diverse patient population; - To develop testing strategies and recommendations for screening asymptomatic populations for HSV-2.

NCT ID: NCT00808405 Completed - Genital Herpes Clinical Trials

GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women

PK/GUD
Start date: January 2009
Phase: N/A
Study type: Interventional

To examine the time to healing of genital lesion and duration of herpes simplex virus (HSV) shedding from genetic ulcer disease (GUD) among 90 HIV-negative African women who have a history of GUD and are HSV-2 seropositive and HIV-1 seronegative randomized in a 2:1 ratio to receive episodic acyclovir 400mg orally three times daily or matching placebo three times daily for 5 days and who are followed for a total of 13 days.

NCT ID: NCT00740584 Completed - HIV Infections Clinical Trials

Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

Start date: August 2008
Phase: Phase 1/Phase 2
Study type: Interventional

To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013 in the vagina. There is no hypothesis for this study.

NCT ID: NCT00723229 Completed - Genital Herpes Clinical Trials

A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation

Start date: August 2008
Phase: Phase 4
Study type: Interventional

We propose to study the episode rate, duration, and quantity of HSV-2 genital shedding in patients taking standard, FDA approved, CDC recommended doses of acyclovir (400 mg PO BID) for HSV-2 suppression compared to taking no medication to better define the effect of acyclovir on short bursts of rapidly cleared HSV-2 shedding. This study will be a randomized, open label, cross-over trial. We hypothesize that short bursts of HSV-2 reactivation will not be suppressed by acyclovir.

NCT ID: NCT00699764 Completed - Herpes Simplex Clinical Trials

Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease

Start date: March 1996
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the safety of Herpes Simplex candidate vaccine (gD2t) with adjuvant and its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease.

NCT ID: NCT00527618 Completed - HIV Infection Clinical Trials

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

Start date: December 2007
Phase: Phase 4
Study type: Interventional

To compare the effect of high-dose valacyclovir (1 gram orally twice daily) versus standard-dose acyclovir (400 mg orally twice daily) on the frequency of genital HSV reactivation and on plasma HIV-1 levels among HSV-2/HIV-1 co-infected individuals. The investigators hypothesize that high-dose valacyclovir will result in greater reduction in plasma HIV-1 and genital HSV reactivation.

NCT ID: NCT00495573 Completed - Genital Herpes Clinical Trials

HSV-2 Shedding Resolution After Acyclovir Treatment

Start date: June 2007
Phase: N/A
Study type: Observational

The purpose of the study is to evaluate the pattern of viral shedding after beginning treatment with acyclovir for a clinical recurrence of genital herpes and to compare it with the pattern of viral shedding during an untreated clinical recurrence of genital herpes.

NCT ID: NCT00486200 Completed - Herpes Genitalis Clinical Trials

A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

Start date: June 21, 2007
Phase: Phase 2
Study type: Interventional

A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.